Related Experiment Video
Updated: Nov 11, 2025
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Prognostic significance of FSCN family in multiple myeloma
Cong Deng1, Chaozeng Si2, Xu Ye3
1Department of Clinical laboratory, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Abstract:
Multiple myeloma (MM) is a hematologic tumor with monoclonal proliferation of malignant plasma cells in the bone marrow. Fascin (FSCN) is an actin-binding protein that plays a crucial role in cell migration and invasion, contributing to tumor metastasis. There are three members (FSCN1-3) in FSCN family. However, the prognostic role of FSCN family in MM remains unclear. In this study, we used four independent Gene Expression Omnibus (GEO) datasets to explore the relationships between FSCN1-3 expression profiles and patient survival in MM. We found that FSCN1 was dramatically down-regulated in MM compared to normal donors (p < 0.001) and monoclonal gammopathy of undetermined significance (MGUS) (p = 0.032). Patients with high expression of FSCN1 and FSCN2 had significantly longer OS (p = 0.023 and 0.028, respectively). Univariate and multivariate analysis showed that FSCN1 (p = 0.003, 0.002) and FSCN2 (p = 0.018, 0.013) were independent favorable prognostic factors for OS in MM. Moreover, the combination of high expression of FSCN1 and FSCN2 could effectively predict both longer EFS (p = 0.046) and OS (p = 0.015). Our study suggested that FSCN1 and FSCN2 can be used as favorable biomarkers for predicting clinical outcomes in MM.
Insights
Fascin (FSCN) proteins FSCN1 and FSCN2 are down-regulated in multiple myeloma (MM). High expression of FSCN1 and FSCN2 predicts longer overall survival (OS) and event-free survival (EFS) in MM patients.
Area of Science:
- Hematologic Oncology
- Molecular Biology
- Cancer Biomarkers
Background:
- Multiple myeloma (MM) is a cancer of malignant plasma cells in bone marrow.
- Fascin (FSCN) proteins are actin-binding proteins involved in cell migration and metastasis.
- The prognostic significance of the FSCN family in MM is not well understood.
Purpose of the Study:
- To investigate the prognostic role of FSCN family members (FSCN1-3) in multiple myeloma.
- To explore the relationship between FSCN gene expression and patient survival outcomes in MM.
Main Methods:
- Utilized four independent Gene Expression Omnibus (GEO) datasets for analysis.
- Examined FSCN1-3 expression profiles in MM patients versus normal donors and monoclonal gammopathy of undetermined significance (MGUS).
- Performed univariate and multivariate analyses to assess prognostic value for overall survival (OS) and event-free survival (EFS).
Main Results:
- FSCN1 was significantly downregulated in MM compared to normal and MGUS samples.
- High expression of FSCN1 and FSCN2 correlated with significantly longer OS in MM patients.
- FSCN1 and FSCN2 were identified as independent favorable prognostic factors for OS.
- Combined high expression of FSCN1 and FSCN2 predicted longer EFS and OS.
Conclusions:
- FSCN1 and FSCN2 expression levels are associated with clinical outcomes in multiple myeloma.
- FSCN1 and FSCN2 may serve as valuable biomarkers for predicting prognosis in MM patients.
- Further research into the role of FSCN1 and FSCN2 in MM pathogenesis is warranted.
